Review: Innovative Approaches to Develop, Implement AI-Based Pharmacovigilance Systems

The field of pharmacovigilance is going through a transformative phase driven by changes to regulatory requirements, increased use of social media and an increase in data volume and sources.

This webinar will review approaches to develop and implement AI-based pharmacovigilance systems. Attendees will learn how to respond to these changes while keeping the focus on the safety of patients and consumers. The featured speakers will review innovative approaches regarding how pharmaceutical companies and CROs can collaborate and navigate this dynamic landscape.

Join this webinar with leaders from the pharmaceutical and CRO industries to explore approaches and considerations to using AI to address challenges in patient safety.

Join Dinesh Kasthuril, Head, Global Client Relations & Project Management, Labcorp Patient Safety Solutions; Shalin Patel, Sr. Director, Safety Evaluation and Reporting, Johnson & Johnson; Marina Suvakov, Global Head, Product Safety Surveillance, Philip Morris International; and Michael Murphy, Executive Director, Head of Pharmacovigilance Operations, Amgen, for the live webinar on Wednesday, March 22, 2023, at 11am EDT (4pm CET/EU-Central).

For more information, or to register for this event, visit Approaches to Developing an AI-based Pharmacovigilance System - Automation is Changing the Way Pharma Manages Pharmacovigilance.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.